Inventprise

Edit info

Founded: 2012

Location: Redmond, WA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Pneumococcal Conjugate Vaccine

Drug types: INF, VAC

Lead product: PCV-25

Funding: $30M Apr 2022

Investors: Bill & Melinda Gates Foundation

inventprise.com

linkedin.com

job board

Drug notes:

GBS-06 Clin0 Strep; Shigella-04 RD Shigella; Klebsiella vaccine RD Klebsiella; RSV Vaccine RD RSV

About:

Inventprise is developing innovative and affordable vaccines to bring health to the masses and provide protection against pathogenic strains of infectious diseases. Using their Linker Conjugation platform, Inventprise is creating vaccines that last-longer within patients enabling better coverage and a stronger immune response to be generated. The platform uses their proprietary scalable conjugation technology that can be used to create highly immunogenic and broad spectrum conjugate vaccines. Inventprise’s lead candidate, PCV-25, is a Pneumococcal Conjugate Vaccine, however their robust pipeline also includes investigational vaccines for group B streptococcus and Shigella.